SCHEMBL26445188

SCHEMBL26445188

CC(C)CCCCCCCCCC(=O)NC1CCC(OC(C)C)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 8/20 0.52
CNR2 P34972 8/20 0.52
SMN1; SMN2 Q16637 1/20 0.46
HDAC3 O15379 2/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC2 Q92769 2/20 0.44
HDAC10 Q969S8 2/20 0.44
HDAC11 Q96DB2 2/20 0.44
HDAC8 Q9BY41 2/20 0.44
HDAC6 Q9UBN7 2/20 0.44
NCOR2 Q9Y618 1/20 0.44
SMYD3 Q9H7B4 1/20 0.43
GNAI3 P08754 1/20 0.43
GNAO1 P09471 1/20 0.43
GNAI1 P63096 1/20 0.43
KDM4C Q9H3R0 2/20 0.38
KDM4A O75164 1/20 0.38
PHF8 Q9UPP1 1/20 0.38
KDM2A Q9Y2K7 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24848311 1.00 CNR1 (0.52) CNR1CNR2SMN1; SMN2HDAC3HDAC1
SCHEMBL26445143 0.84 CNR2 (0.52) CNR1CNR2SMN1; SMN2HDAC3HDAC1
SCHEMBL26445149 0.84 CNR2 (0.52) CNR1CNR2SMN1; SMN2HDAC3HDAC1
SCHEMBL104430 0.82 SMN1; SMN2 (0.57) CNR1CNR2SMN1; SMN2HDAC3HDAC1
SCHEMBL28342679 0.81 SMN1; SMN2 (0.72) CNR1CNR2SMN1; SMN2HDAC3HDAC1
SCHEMBL26445192 0.76 CNR1 (0.40) CNR1CNR2SMN1; SMN2MEN1MAPT
SCHEMBL24848310 0.76 CNR1 (0.40) CNR1CNR2SMN1; SMN2MEN1MAPT
SCHEMBL25030382 0.76 SMYD3 (0.39) CNR1CNR2SMN1; SMN2HDAC3HDAC1
SCHEMBL16522418 0.75 SMN1; SMN2 (0.50) CNR1CNR2SMN1; SMN2HDAC3HDAC1
SCHEMBL23100925 0.75 SMN1; SMN2 (0.44) CNR1CNR2SMN1; SMN2HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 US disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF MKNK2, MKRN3, DUS2 CNR1 2314/4885CNR2 716/4885SMN1; SMN2 3385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.